Press Releases

 Filter by Provider

Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or “the Company”), a leader in sustainable, grid-scale energy storage solutions, today announced financial results for the fourth quarter and year ended December 31, 2025.

lululemon athletica inc. (NASDAQ:LULU) today announced the appointment of Chip Bergh, former President and Chief Executive Officer of Levi Strauss & Co., to its Board of Directors, effective immediately. With this addition, lululemon has added five new independent directors to the Board in the last five years, reflecting the Board's commitment to ongoing refreshment.

PagerDuty, Inc. (NYSE:PD), a leader in AI-first operations management, today published the 2026 State of AI-First Operations Report, which illustrates how the financial stakes of extended service disruption has made operational resilience the top priority, and how the growing trust in AI for digital operations contributes to revenue growth. The report draws insights based on survey responses from 1,000 business leaders, IT decision makers and senior developers across Australia and New Zealand, France, Germany, Japan, the Nordic countries, the United Kingdom and Ireland, and the United States.

NextNav Inc. (NASDAQ: NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported its financial results and operational updates for the quarter ended and full year December 31, 2025.

Reports Positive FY 2025 EBITDA

Hinge Health, Inc. (NYSE: HNGE) today announced the addition of Tyler Sloat to its board of directors. Sloat currently serves as the Chief Financial Officer and Chief Operating Officer of Freshworks Inc., where he oversees accounting, finance, IT, security, workplace, corporate strategy and revenue enablement.

Titan America SA (NYSE: TTAM) (“Titan America”) today announced that its Board of Directors has declared a distribution of $0.04 per common share for the first quarter of 2026 out of Titan America’s available issue premium. The distribution of $0.04 per common share will be payable on May 8, 2026, to shareholders of record as of April 20, 2026.

Limbach Holdings, Inc. (Nasdaq: LMB) (“Limbach” or the “Company”), a building systems solutions firm that partners with building owners and operators who have mission-critical mechanical, electrical, plumbing and controls (“MEPC”) systems, today announced that Michael McCann, President and Chief Executive Officer, will participate in the ROTH 38th Annual Conference for Growth Companies in Dana Point, California on Monday, March 23rd and Tuesday, March 24th, 2026.

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended December 31, 2025, and provided a business update. Management will host a conference call and webcast today at 4:30 p.m. ET.

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States

RESTON, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today reported financial results for the fourth quarter and full year ended December 31, 2025.

HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the "Company") a leading specialty construction company, today announced that Thomas (“Tom”) N. Amonett, who has served as an independent member of the Company’s Board of Directors (the “Board”) and Audit Committee since 2007 and Chairman of the Nominating & Governance Committee from 2007 to 2025, informed the Company that he has chosen not to stand for re-election and instead retire from the Board effective at the Company’s upcoming Annual General Meeting of Stockholders on May 19, 2026.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endeavor Group Holdings, Inc. (“Endeavor” or the “Company”) (NYSE: EDR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Sudbury, ON - ANNA Autism Care proudly announces the continued expansion of comprehensive therapy programs designed to support children and families navigating autism spectrum disorder. With a strong commitment to evidence-based practices and individualized care, the organization delivers structured, compassionate services tailored to each client’s developmental goals.

RENO, Nev., March 17, 2026 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (“Company” or “Ormat”) announced today its intention to offer $600 million aggregate principal amount of Series A Convertible Senior Notes due 2031 (the “Series A Notes”) and $150 million aggregate principal amount of Series B Convertible Senior Notes due 2031 (the “Series B Notes” and, together with the Series A Notes, the “Notes”) in private offerings to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. The Company also expects to grant to the initial purchasers options to purchase, in each case within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $90 million aggregate principal amount and $22.5 million aggregate principal amount of Series A Notes and Series B Notes, respectively.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) --

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Plug Power Inc. (“Plug Power” or the “Company”) (NASDAQ: PLUG) and certain officers.   The class action, filed in the United States District Court for the Northern District of New York, and docketed under 26-cv-00165, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Plug Power securities between January 17, 2025 and November 13, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Oracle Corporation (“Oracle” or the “Company”) (NYSE: ORCL).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

Forum & Social, a new private gathering concept founded by Drew Clark, has announced plans to launch across five Southeastern cities this summer. The venues will open in Atlanta, Charlotte, Jacksonville, Orlando, and Tampa and are designed for organizations that require structured environments for leadership meetings, client hosting, and donor engagement.

Sprouts Farmers Market, Inc. (Nasdaq: SFM), one of the largest and fastest-growing specialty retailers of fresh, natural and organic food in the United States, today announced the company’s participation in the 38th Annual ROTH Conference in Dana Point, CA. Jack Sinclair, chief executive officer, and Curtis Valentine, chief financial officer, are scheduled to conduct a fireside chat discussion at 8:30 a.m. Pacific Time on Tuesday, March 24, 2026.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.

Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.

Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock). SAB BIO also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of the shares (and any pre-funded warrants) in the proposed offering are to be sold by SAB BIO.

BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026. 

The FDA approval of Tirzepatide for children age 10 and older marks one of the most meaningful advances in pediatric metabolic care in a generation. Youth-onset type 2 diabetes progresses faster than adult disease, often overlapping with obesity, insulin resistance, and early cardiovascular risk. California Trim Clinic examines the pivotal clinical evidence behind the approval and explains why this shift in treatment strategy is redefining what treatment can look like for younger patients. For families navigating youth metabolic disease, physician-guided programs such as TeenHealthRx, developed by California Trim Clinic to support adolescents nationwide, are beginning to translate these scientific breakthroughs into real clinical care.

CaoCao Inc. today announced new progress in its Robotaxi operations: the company has activated more than 3,600 virtual pick-up and drop-off points across Hangzhou’s Binjiang District and the central area of Xiaoshan District, achieving near full coverage of major roads, office buildings, and entrances to residential and mixed-use communities within the operating area.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ORLANDO, FL / ACCESS Newswire / March 17, 2026 / Laser Photonics Corporation (NASDAQ:LASE) (the "Company"), a global leader in laser systems for industrial and defense applications, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,373,630 shares of common stock of the Company originally issued in September 2025, having an exercise price of $3.40 per share, at a reduced exercise price of $1.08 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-290875). The gross proceeds to the Company from the exercise of the warrants were approximately $1.5 million, prior to deducting placement agent fees and estimated offering expenses.

Institutional investors holding positions in monday.com Ltd. (NASDAQ: MNDY) during the period September 17, 2025 through February 6, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025.

Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GoDaddy Inc. (“GoDaddy” or the “Company”) (NYSE: GDDY) investors concerning the Company’s possible violations of the federal securities laws.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of DNOW Inc. (“DNOW” or the “Company”) (NYSE: DNOW) investors concerning the Company’s possible violations of the federal securities laws.

Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Tennant Company (“Tennant” or the “Company”) (NYSE: TNC) investors concerning the Company’s possible violations of the federal securities laws.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) investors concerning the Company’s possible violations of the federal securities laws.

Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, today announced a leading U.S. based semiconductor manufacturer and foundry services company placed a multi-unit order for the Eclipse platform to support development and manufacturing of next‑generation high‑performance computing (HPC) and artificial intelligence (AI) datacenter processors.

Levi & Korsinsky, LLP encourages investors who suffered losses in Snowflake Inc. (NYSE: SNOW) to contact the firm. WHO IS AFFECTED: Those who purchased SNOW securities between June 27, 2023 and February 28, 2024 may be entitled to recover damages. Find out if you are eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Levi & Korsinsky, LLP alerts investors in NuScale Power Corporation (NYSE: SMR) of a pending securities class action naming two senior executives as individual defendants under Section 20(a) of the Securities Exchange Act of 1934. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who purchased AQST securities between June 16, 2025 and January 8, 2026 lost over 37% of their investment value in a single trading session. Find out if you qualify to recover your investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Stephen Pakola, M.D., REGENXBIO's (NASDAQ: RGNX) Executive Vice President and Chief Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing at $11.01.

The promise: guaranteed returns of 80% to 300% on a stock poised for acquisition at a premium. The reality: a 94.1% single-day collapse that destroyed $950 million in market capitalization, leaving thousands of investors across six countries holding shares worth pennies.

Ecolab will host a live webcast to discuss its first quarter 2026 results. A news release containing first quarter results is expected to be issued before market open on April 28, 2026.

Oklo Inc. (NYSE: OKLO) (“Oklo” or “the Company”), an advanced nuclear technology company, today published its financial results and business update for the quarter and year ended December 31, 2025.

Levi & Korsinsky, LLP reminds purchasers of Boston Scientific Corporation (NYSE: BSX) securities of a pending securities class action.

Institutional investors holding positions in Enphase Energy, Inc. (NASDAQ: ENPH) during the period April 22, 2025 through October 28, 2025 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Levi & Korsinsky, LLP examines the adequacy of Franklin BSP Realty Trust, Inc.'s (NYSE: FBRT) risk disclosures during the period November 5, 2024 through February 11, 2026. Shareholders who lost money on FBRT may find out if you are eligible to pursue a recovery claim or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.